Nanjing AscendRare Pharmaceutical Technology Co., Ltd according to the industry direction of the new R&D institution, mainly conducts pancreatic islet research for diabetes and research and development of new drugs for neonatal hypoglycemia.
Neonatal hypoglycemia is a serious neonatal disease, which belongs to the category of rare diseases. The cause is hyperinsulinemic hypoglycemia which induced by excessive or improper secretion of insulin, mainly caused by mutations in genes that regulate some key enzymes or ion channels in the insulin secretion pathway.The disease accompanies the patient for a lifetime, and the frequency of hypoglycemia in adulthood is reduced, but medical intervention is still needed. If effective treatment is not carried out in time, it will not only cause irreversible damage to brain function but even threaten life in severe cases. The current treatment methods are very limited, and patients urgently need new treatment drugs.
The company was established in September 2018 and has received funding from Nanjing Jiangbei New District, Nanjing Innovative Talents, and Jiangsu Double Innovation Talents Project. After that, through the application of scientific research projects, they applied individually or cooperatively to obtain funding for several national and provincial scientific research projects.
In 2020, two years after the company was established, after the gradual improvement of R&D technology, platform construction, and R&D personnel, based on the principle of “the same target, from rare diseases to common diseases”, the company’s development goals have gradually expanded from rare diseases to common diseases, including diabetes, fatty liver, and tumor metabolism.
The company has a strong R&D team with 8 core R&D employees, including 2 doctors and 6 masters. The core R&D personnel have rich research and R&D experience. Intellectual property, as the most important intellectual asset of an enterprise, is an important source of promoting scientific and technological innovation and enhancing the core competitiveness of enterprises. At present, AscendRare has applied for nearly 20 invention patents.